Correlation Analysis of Serum IGF-1 VEGF and TSH Index Expression Levels with the Progression of Cognitive Impairment to Dementia in Patients with Cerebral Small Vessel Disease
BAI Yanchang, CHEN Shanpeng, SUN Qianyu, et al
The First Hospital of Qinhuangdao, Hebei Qinhuangdao 066000, China
Abstract:Objective: To explore the correlation between the expression levels of serum insulin-like growth factor-1 (IGF-1), vascular endothelial growth factor (VEGF), and thyroid-stimulating hormone (TSH) index, and the progression of cognitive impairment to dementia in cerebral small vessel disease (CSVD), to provide a reference for clinical prevention and treatment. Methods: A total of 210 CSVD patients with cognitive impairment admitted to the hospital from May 2020 to May 2023 were selected and treated with symptomatic treatment. They were followed up for 1 year and assigned to a dementia group and a non-dementia group based on whether their cognitive impairment progressed to dementia. Clinical data were collected from all patients, and 5 mL of fasting venous blood was collected early in the morning of the day following the admission of all patients to detect the levels of serum IGF-1, VEGF, and TSH indices. The clinical data, serum levels of IGF-1, VEGF, and TSH indices were compared between the two groups, the correlation between serum levels of IGF-1, VEGF, and TSH indices and the severity of cognitive impairment and dementia was analyzed, the predictive value of each serum marker for the progression of CSVD cognitive impairment to dementia was evaluated. Results: Compared with the non-dementia group, the dementia group had higher proportions of alcohol consumption, family history of dementia, and total CSVD imaging burden scores at baseline, as well as lower MoCA scores and proportions of regular anti-cognitive impairment treatment at baseline (all P<0.05). Compared with the non-dementia group (97.28±14.15) ng/mL, (248.77±40.61) ng/L, and (133.27±13.58) mIU/L, the dementia group had lower serum IGF-1 and VEGF levels [(83.65±10.40) ng/mL and (210.49±35.23) ng/L, respectively], and a higher TSH index level (151.45±18.72) mIU/L (t=5.471, 5.762, 6.791, all P<0.05); serum IGF-1 and VEGF were negatively correlated with the total burden score of CSVD imaging at baseline, and positively correlated with MoCA score; the TSH index was positively correlated with the total burden score of CSVD imaging at baseline, and negatively correlated with MoCA score (P<0.05). Before and after correcting other factors, serum IGF-1, VEGF, and TSH indices were still independently associated with the progression of CSVD cognitive impairment to dementia (P<0.05). The AUCs of serum IGF-1, VEGF, and TSH index for predicting the progression of CSVD cognitive impairment to dementia were 0.776 (95%CI: 0.713~0.831), 0.812 (95%CI: 0.752~0.863), and 0.821 (95%CI: 0.762~0.871), respectively; the AUC of the three combined predictors for the progression of CSVD cognitive impairment to dementia was 0.932 (95%CI: 0.888~0.962), with a sensitivity of 88.89% and a specificity of 84.71%; the predictive value was significantly higher than that of each predictor (P<0.05). Conclusion: The serum levels of IGF-1, VEGF, and TSH indices are significantly correlated with the condition of patients with CSVD cognitive impairment, which are independent factors contributing to the progression to dementia, and their combined predictive value is reliable.
白彦昌, 陈善鹏, 孙倩玉, 张亚杰. 血清IGF-1 VEGF TSH指数表达水平与脑小血管病认知障碍进展至痴呆的相关性分析[J]. 河北医学, 2025, 31(5): 788-793.
BAI Yanchang, CHEN Shanpeng, SUN Qianyu, et al. Correlation Analysis of Serum IGF-1 VEGF and TSH Index Expression Levels with the Progression of Cognitive Impairment to Dementia in Patients with Cerebral Small Vessel Disease. HeBei Med, 2025, 31(5): 788-793.
[1] Hainsworth AH,Markus HS,Schneider JA.Cerebral small vessel disease, hypertension, and vascular contributions to cognitive impairment and dementia[J].Hypertension,2024,81(1): 75-86. [2] Tang WY,Zhang M,Wang Y,et al.IGF-1 inhibits palmitic acid-induced mitochondrial apoptosis in macrophages[J].Mol Med Rep,2023,28(6): 234. [3] Zarezadehmehrizi A,Hong J,Lee J,et al.Exercise training ameliorates cognitive dysfunction in amyloid beta-injected rat model:possible mechanisms of Angiostatin/VEGF signaling[J].Metab Brain Dis,2021,36(8): 2263-2271. [4] van Vliet NA,van Heemst D,Almeida OP,et al.Association of thyroid dysfunction with cognitive function:an individual participant data analysis[J].JAMA Intern Med,2021,181(11): 1440-1450. [5] 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国脑小血管病诊治指南2020[J].中华神经科杂志,2022,55(8): 807-818. [6] Staals J,Makin SD,Doubal FN,et al.Stroke subtype, vascular risk factors, and total MRI brain small-vessel disease burden[J].Neurology,2014,83(14): 1228-34. [7] Jia XF,Wang ZH,Huang FF,et al.A comparison of the mini-mental state examination (MMSE) with the montreal cognitive assessment (MoCA) for mild cognitive impairment screening in Chinese middle-aged and older population:a cross-sectional study[J].BMC Psychiatry,2021,21(1): 485. [8] 中国痴呆与认知障碍指南写作组,中国医师协会神经内科医师分会认知障碍疾病专业委员会.2018中国痴呆与认知障碍诊治指南(一): 痴呆及其分类诊断标准[J].中华医学杂志,2018,98(13): 965-970. [9] 游婷婷.缺血性脑小血管病患者血清β淀粉样蛋白1-42、脑源性神经营养因子、胰岛素样生长因子-1水平与血管性认知功能障碍的相关性分析[J].实用医院临床杂志,2022,19(1): 121-124. [10] Sui GH,Yang CX,Wang L,et al.Exogenous IGF-1 improves tau pathology and neuronal pyroptosis in high-fat diet mice with cognitive dysfunction[J].Metab Brain Dis,2021,36(7): 2079-2088. [11] Requena-Ocana N,Flores-Lopez M,Papaseit E,et al.Vascular endothelial growth factor as a potential biomarker of neuroinflammation and frontal cognitive impairment in patients with alcohol use disorder[J].Biomedicines,2022,10(5): 947. [12] 王龙海,黄志强.脑小血管病所致血管性认知功能障碍患者VEGF hs-CRP水平及脑血流灌注的临床意义[J].中国实用神经疾病杂志,2022,25(10): 1226-1231. [13] Chukaew P,Bunmak N,Auampradit N,et al.Correlation of BDNF, VEGF, TNF-α, and S100B with cognitive impairments in chronic, medicated schizophrenia patients[J].Neuropsychopharmacol Rep,2022,42(3): 281-287. [14] Nicola Marioara OM,Popescu M,VlaDOIanu CN,et al.Study of cognitive disfunctions in thyroid pathology[J].Curr Health Sci,2021,47(2): 256-262. [15] Marty MS,Sauer UG,Charlton A,et al.Towards a science-based testing strategy to identify maternal thyroid hormone imbalance and neurodevelopmental effects in the progeny-part III:how is substance-mediated thyroid hormone imbalance in pregnant/lactating rats or their progeny related to neurodevelopmental effects[J].Crit Rev Toxicol,2022,52(7): 546-617.